Consensus Algorithm Pairs Alopecia Areata Severity With Quality of Life Impact

A standard hair-loss measurement can miss what matters most to a patient with alopecia areata (AA): how quickly the disease is moving, whether eyebrows and eyelashes are affected, and how heavily it weighs on daily life.

A panel of 8 Canadian dermatologists built those factors into a new consensus-based algorithm for matching therapy to disease severity in adolescents and adults.

Beyond the SALT Score

AA is an autoimmune, relapsing, non-scarring hair loss disorder that affects roughly 2% of the population, ranging from small scalp patches to complete loss of scalp hair (alopecia totalis) or all body hair (alopecia universalis).¹

The disease frequently coexists with other autoimmune conditions, including thyroid disease, vitiligo, and psoriasis, and patients with AA carry higher rates of anxiety, depression, and suicidal ideation than the general population.

Treatment options were historically limited, but newer therapies are now regrowing hair for patients whom older approaches could not help, even though relapse within 5 years of regrowth remains common, the American Academy of Dermatology noted.²

Advances in Janus kinase (JAK) inhibition drove much of that shift, but guidance on escalating care based on quality of life and disease dynamics had lagged behind the science.¹

The consensus algorithm was designed to close that gap.

Building the Algorithm

The panel of 8 Canadian dermatologists convened November 16, 2024, during the Dermatology Update Conference in Montreal, Quebec. Using a modified Delphi process aligned with the AGREE (Appraisal of Guidelines for Research and Evaluation) II framework, the group refined the algorithm through small-group and plenary sessions, with consensus defined as 75% agreement in blinded voting.

Two reviewers led a structured PubMed search, supplemented by Google Scholar, spanning January 2015 through July 2024. Of 72 identified articles, 40 met inclusion criteria, including 12 randomized controlled trials, 5 systematic reviews, and 4 meta-analyses. The highest-quality evidence supported oral JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—for moderate to severe AA, while topical and intralesional corticosteroids were represented mostly by lower-level, real-world evidence.

A Broader Definition of Severity

Rather than relying on the Severity of Alopecia Tool (SALT) score alone, which scores scalp hair loss by quadrant, the algorithm adopted a modified AA scale that could bump a patient up one severity tier when eyebrow or eyelash involvement, meaningful psychosocial impact, an inadequate response after at least 6 months of treatment, or rapidly progressive hair loss was present. Under the base SALT categories, mild AA was defined as less than 20% scalp hair loss, moderate AA as 21% to 49%, and severe AA as 50% to 100%.

“Experts agreed that an inadequate response would be a decision made by the patient and clinician, as response to therapy can be variable,” the authors wrote.

Core options for mild AA included topical and intralesional corticosteroids, with or without topical minoxidil; insufficient response opened the door to intramuscular corticosteroids, oral minoxidil, or topical calcineurin inhibitors. Moderate AA added systemic corticosteroids, escalating to contact sensitizers, topical JAK inhibitors, or oral immunosuppressants such as methotrexate or cyclosporine for nonresponders.

Severe AA, or 50% or more scalp hair loss, relied on the oral JAK inhibitors baricitinib and ritlecitinib as core therapy. In the pivotal ALLEGRO-2b/3 trial, 23% of patients with severe AA treated with 50 mg daily ritlecitinib achieved a SALT score of 20 or less by week 24, vs 1.6% on placebo; with an initial loading dose, that figure reached 43% by week 48. Baricitinib showed a similar pattern in the BRAVE-AA1 (NCT03570749) and for BRAVE-AA2 trials (NCT03899259), with 38.8% and 35.9% of patients on the 4-mg dose, respectively, reaching that threshold by week 36. Both drugs produced eyebrow and eyelash regrowth, a domain scalp-focused scores often miss.

Safety data were reassuring: among 1628 patients treated with ritlecitinib, headache, diarrhea, and acne were the most common adverse events, at rates similar to placebo, with no signal for malignancy, thrombosis, or major cardiovascular events. Oral JAK inhibitors still carry a boxed warning for infection, malignancy, and thrombosis that the panel said warranted caution in patients older than 65 years or with a history of malignancy or thromboembolic disease.

Where the Algorithm Stops Short

The panel was explicit about what its algorithm does not cover: long-term management, de-escalation, and relapse fell outside the Delphi process, and future work must define drug-monitoring strategies for patients who remain on a JAK inhibitor for years. Guidance on beard alopecia was also left out, since the panel did not discuss it.

The project was supported by an unrestricted educational grant from Pfizer Canada, which markets ritlecitinib, though the panel said development proceeded independently of industry sponsorship and that panelists disclosed conflicts of interest.

For clinicians, payers, and patients navigating a crowded field of AA therapies, the algorithm's central message was that severity is not just a hair-loss percentage. Its authors said validating the approach in real-world cohorts and ensuring equitable access to newer JAK inhibitors would determine whether it changes practice beyond the consensus room where it was built.

References

1. Lynde CW, Guenther L, Andriessen A, Hanna S, Netchiporouk E, Prajapati V, Wiseman M, Ringuet J. A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics. Front Med. 2026;13:1846243. doi:10.3389/fmed.2026.1846243
2. American Academy of Dermatology Association. Hair loss types: alopecia areata overview. Updated August 30, 2023. Accessed August 24, 2026. https://www.aad.org/public/diseases/hair-loss/types/alopecia